Philip R. Greipp

Q: What Schools Are Affiliated With Philip R. Greipp

Philip R. Greipp is affiliated with the following schools: Indiana University, University of Minnesota, University of Salamanca

Philip R. Greipp's AcademicInfluence.com Rankings

Philip R. Greipp

Philosophy

#5645

World Rank

#8510

Historical Rank

Logic

#2882

World Rank

#3953

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Philip R. Greipp Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philip R. Greipp's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Improved survival in multiple myeloma and the impact of novel therapies. (2008) (2142)
Review of 1027 patients with newly diagnosed multiple myeloma. (2003) (2065)
International staging system for multiple myeloma. (2005) (1929)
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. (2007) (1032)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. (2010) (879)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. (2006) (868)
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (834)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. (2004) (748)
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012) (740)
POEMS syndrome: definitions and long-term outcome. (2003) (695)
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. (1997) (664)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005) (649)
Clinical and biologic implications of recurrent genomic aberrations in myeloma. (2003) (625)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009) (609)
Genetics and Cytogenetics of Multiple Myeloma (2004) (566)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. (2002) (535)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. (2006) (494)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. (2004) (489)
Smoldering multiple myeloma. (1980) (454)
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. (1985) (426)
A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases (2003) (395)
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. (1992) (380)
Prognostic value of bone marrow angiogenesis in multiple myeloma. (2000) (378)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. (2005) (349)
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. (2004) (327)
Genomic abnormalities in monoclonal gammopathy of undetermined significance. (2002) (325)
Clinical course of patients with relapsed multiple myeloma. (2004) (321)
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. (2009) (309)
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. (2002) (305)
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. (1993) (304)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2004) (303)
Genetic aberrations and survival in plasma cell leukemia (2008) (295)
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. (2002) (291)
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. (2003) (286)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. (2007) (261)
Amyloidosis (AL). Clinical and laboratory features in 229 cases. (1983) (253)
Multiple myeloma: significance of plasmablastic subtype in morphological classification. (1985) (245)
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. (2009) (241)
Narrative Review: The Systemic Capillary Leak Syndrome (2010) (236)
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. (2006) (235)
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2006) (230)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. (2010) (229)
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma (2003) (227)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. (2007) (226)
Thalidomide as initial therapy for early-stage myeloma (2003) (224)
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. (2004) (215)
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. (2010) (212)
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. (1996) (212)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. (2005) (211)
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. (1986) (205)
Systemic therapy of myeloma xenografts by an attenuated measles virus. (2001) (203)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma (2006) (200)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy (2007) (199)
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years (1996) (194)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) (193)
Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia (2004) (190)
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. (1988) (189)
Thalidomide in the treatment of relapsed multiple myeloma. (2000) (187)
Long-term survival (10 years or more) in 30 patients with primary amyloidosis. (1999) (187)
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. (1998) (187)
Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. (1992) (186)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. (2007) (186)
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. (2002) (186)
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. (2008) (185)
Response rates and survival in primary systemic amyloidosis. (1991) (185)
Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells (2007) (185)
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. (2006) (181)
Thalidomide for previously untreated indolent or smoldering multiple myeloma (2001) (180)
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia (1990) (176)
Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) (2004) (175)
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. (2002) (174)
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. (2011) (167)
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. (2011) (164)
Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil (2000) (157)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. (2007) (155)
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system (2008) (153)
Expression of VEGF and its receptors by myeloma cells (2003) (152)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells (2007) (150)
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group (2007) (150)
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). (2012) (150)
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. (2004) (149)
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report (2004) (149)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. (2001) (148)
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. (1978) (148)
Appraisal of immunoglobulin free light chain as a marker of response. (2008) (143)
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. (2013) (143)
Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. (1985) (142)
Factor‐X deficiency in amyloidosis: A critical review (1981) (142)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. (2009) (141)
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. (2009) (141)
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. (2010) (139)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis (2003) (139)
Clinical significance of TP53 mutation in myeloma (2007) (137)
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. (2003) (133)
Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. (1983) (132)
A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. (1998) (130)
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations (2006) (128)
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. (2001) (127)
Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia (2006) (126)
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. (2004) (123)
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. (2004) (123)
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. (1996) (120)
A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. (2006) (118)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. (2012) (117)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. (2010) (116)
A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. (1985) (116)
Treatment of the Systemic Capillary Leak Syndrome with Terbutaline and Theophylline: A Case Series (1999) (115)
Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. (1994) (115)
CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. (1994) (112)
Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) (2006) (111)
S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. (1986) (111)
Current therapy for multiple myeloma. (2002) (110)
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. (2006) (109)
Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma (1993) (109)
Localization of eosinophil granule major basic protein in human basophils (1983) (108)
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. (1996) (107)
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. (2005) (107)
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. (2009) (106)
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. (2010) (106)
Factor X deficiency in primary amyloidosis: resolution after splenectomy. (1979) (105)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. (2005) (104)
Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. (1996) (103)
"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. (1982) (102)
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis (2011) (102)
Prognostic value of angiogenesis in solitary bone plasmacytoma. (2003) (101)
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. (1999) (101)
Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. (1987) (101)
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis (2007) (99)
Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells (2007) (97)
Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM). (2009) (95)
Anti‐CD20 monoclonal antibody therapy in multiple myeloma (2008) (95)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma (2004) (95)
Multiple myeloma: circulating lymphocytes that express plasma cell antigens. (1984) (94)
A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. (1995) (93)
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. (2006) (92)
Clinical implication of centrosome amplification in plasma cell neoplasm. (2006) (92)
Control of systemic capillary leak syndrome with aminophylline and terbutaline. (1992) (91)
Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. (1995) (91)
Cardiac amyloidosis: a practical approach to diagnosis and management. (2011) (91)
Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma (1994) (90)
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. (2001) (89)
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis (2009) (87)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (2004) (87)
Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases (1998) (86)
Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. (1995) (86)
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. (1996) (86)
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma (2013) (85)
Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. (1984) (82)
CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations (2005) (78)
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients (2000) (78)
Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. (1988) (78)
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. (2007) (77)
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi (2008) (76)
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. (1993) (76)
Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma (1993) (75)
Pyostomatitis vegetans. A reactive mucosal marker for inflammatory disease of the gut. (1985) (75)
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. (1999) (75)
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. (2005) (70)
Trends and outcomes of modern staging of solitary plasmacytoma of bone (2012) (70)
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy (2004) (70)
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders (2007) (70)
Advances in the diagnosis and management of myeloma. (1992) (69)
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma (2007) (69)
Detection of myeloma cells in the peripheral blood by flow cytometry. (1996) (67)
Prognostic factors in multiple myeloma. (1999) (67)
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation (2001) (66)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial (2011) (65)
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. (2003) (65)
Effect of complete response on outcome following autologous stem cell transplantation for myeloma (2000) (63)
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. (2005) (63)
Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. (1997) (63)
Bone marrow angiogenesis in multiple myeloma: effect of therapy (2002) (62)
Autologous stem cell transplantation for relapsed and primary refractory myeloma (1999) (62)
Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. (1985) (61)
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. (1999) (61)
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis (2014) (60)
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival (2008) (60)
Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders (1999) (58)
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma (2004) (58)
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. (2011) (58)
Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. (1982) (57)
Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study (2012) (57)
Chromosomal abnormalities in systemic amyloidosis (1998) (56)
Complete response in multiple myeloma (2006) (55)
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. (2010) (55)
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma (1999) (55)
Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma (1999) (54)
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. (2002) (54)
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. (2008) (53)
Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial (2009) (53)
Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma (2010) (53)
Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU‐1) (1985) (52)
The diverse picture of gamma heavy-chain disease. Report of seven cases and review of literature. (1981) (50)
The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. (1989) (49)
Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis (1999) (49)
Infection and killing of multiple myeloma by adenoviruses. (2010) (48)
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma (2005) (48)
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. (2001) (48)
Detection of hypodiploidy using multi‐parameter flow cytometric analysis: A prognostic indicator in multiple myeloma (1989) (48)
Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial (2010) (47)
Hyposplenism in primary systemic amyloidosis. (1983) (47)
Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma (1995) (46)
Phase II trial of high‐dose dexamethasone for previously treated immunoglobulin light‐chain amyloidosis (1999) (44)
Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. (2006) (44)
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature (2010) (43)
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. (1987) (43)
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma (2010) (42)
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. (2011) (42)
Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. (2006) (42)
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma (2000) (41)
A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study (2004) (41)
Species D Adenoviruses as Oncolytics against B-cell Cancers (2011) (41)
Activating Mutations of Nand Kras in Multiple Myeloma Show Different Clinical Associations : Analysis of the Eastern Cooperative Oncology Group Phase I 11 Trial (2002) (40)
Incidence of corneal crystals in the monoclonal gammopathies. (1989) (40)
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? (1999) (39)
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. (2009) (39)
Waldenström macroglobulinemia: What a hematologist needs to know. (2015) (38)
A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. (1995) (38)
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis (2011) (38)
Plasma cell labeling index. (2005) (38)
Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma (2003) (38)
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma (1999) (37)
Treatment of refractory multiple myeloma and considerations for future therapy. (1986) (37)
Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry. (1990) (37)
Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. (1991) (37)
Proteasome β Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics (2008) (35)
Clinical aspects of pulmonary amyloidosis. (1986) (34)
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. (2007) (34)
Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03 (2011) (33)
Amplification of RNA and DNA specific for erb B in unbalanced 1;7 chromosomal translocation associated with myelodysplastic syndrome (1986) (33)
Thalidomide Plus Dexamethasone Versus Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (E1A00): Results of a Phase III Trial Coordinated by the Eastern Cooperative Oncology Group. (2004) (33)
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. (1999) (32)
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). (1999) (32)
Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. (2010) (31)
Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity? (1995) (31)
Prognosis in myeloma. (1994) (31)
Thalidomide plus dexamethasone (thal/dex) and thalidomide alone (thal) as first line therapy for newly diagnosed myeloma (mm) (2000) (30)
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. (2009) (30)
Beta2-Microglobulin Predicts Survival in Primary Systemic Amyloidosis (1990) (30)
A monoclonal antibody reactive with a subset of human plasma cells (1986) (29)
Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma. (2009) (28)
Long‐term results of single‐agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (2010) (28)
Ploidy status rarely changes in myeloma patients at disease progression. (2006) (28)
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. (2005) (28)
Idiopathic pulmonary hemosiderosis: two cases in a family. (1978) (28)
Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis. (1989) (27)
Multiple myeloma: Houses and spouses (1983) (27)
Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). (1998) (27)
Cardiobacterium hominis endocarditis. Four cases with clinical and laboratory observations. (1978) (27)
Bone marrow angiogenesis and circulating plasma cells in multiple myeloma (2003) (26)
Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. (1992) (26)
Angiogenesis in multiple myeloma. (2001) (25)
Angiogenesis in multiple myeloma (2001) (25)
T cell depletion using anti-CD2 coated magnetic beads simplifies the detection of peripheral blood plasma cells. (1991) (24)
A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. (2004) (24)
Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma (2008) (23)
Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments (2004) (23)
Prosthetic Hip Replacement for Pathologic or Impending Pathologic Fractures in Myeloma (1997) (22)
Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM). (2004) (22)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma (2008) (22)
Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. (2010) (21)
Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma (2006) (21)
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. (2011) (21)
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis (2008) (20)
Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. (1995) (20)
Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486 (1999) (20)
Discoid lupus erythematosus and monoclonal gammopathy (1983) (20)
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. (2009) (20)
Angiogenesis in Waldenstrom's macroglobulinemia. (2003) (19)
Decreased levels of helper T cells in pregnancy. (1982) (19)
Fabrication of gold nanoparticle for potential application in multiple myeloma (2008) (18)
Biology and treatment of myeloma. (1996) (17)
Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice–Certified Tissue Banking Facility (2008) (17)
Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02). (2006) (17)
Immunoglobulin D amyloidosis: a distinct entity. (2012) (16)
t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients (2003) (16)
The treatment of multiple myeloma with docetaxel (an ECOG study). (2003) (16)
A phase ii trial of thalidomide in the treatment of relapsed multiple myeloma (mm) with laboratory correlative studies (2000) (16)
Circulating peripheral blood plasma cells in multiple myeloma. (1992) (15)
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group. (1995) (15)
Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis (1998) (14)
Hematologic malignancies : multiple myeloma and related plasma cell disorders (2004) (14)
Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02). (2007) (14)
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up (2016) (14)
3. The laboratory investigation of monoclonal gammopathies. (1978) (13)
The ( 11 ; 14 ) ( q 13 ; q 32 ) Translocation in Multiple Myeloma A Morphologic and Immunohistochemical Study (2002) (13)
Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? (1995) (13)
Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. (2007) (13)
Narrative Review: Clarkson Disease-Systemic Capillary Leak Syndrome (2010) (13)
Lymphocyte subsets in patients with aplastic anemia (1984) (13)
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. (1995) (13)
The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS). (2009) (13)
Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure. (1989) (12)
Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. (1995) (12)
Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited. (2004) (12)
Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD) (2010) (12)
Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years, (2011) (12)
Molecular and biological role of CD40 in multiple myeloma. (1995) (11)
Amyloidosis (AL). An approach to early diagnosis. (1984) (11)
Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis? (1998) (11)
Beta 2-microglobulin predicts survival in primary systemic amyloidosis. (1990) (11)
Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index. (1991) (11)
Elevated glucocorticoid receptor binding in cultured human lymphoblasts following hydroxyurea treatment: lack of effect on steroid responsiveness. (1986) (11)
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. (2009) (11)
Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis. (2006) (11)
Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score (2010) (10)
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma (2011) (10)
Smoldering, asymptomatic stage 1, and indolent myeloma (2000) (10)
Detection of B-cells clonally related to the tumor population in multiple myeloma and MGUS. (1995) (10)
FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis (2000) (10)
Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System. (2007) (9)
Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study (2004) (9)
Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma (2010) (9)
Hyperpigmentation syndromes (diffuse hypermelanosis) (1978) (8)
Cytogenetic analysis using multiple myeloma targets in POEMS syndrome (2007) (8)
Clinical impact of discordance in serum albumin measurements on myeloma international staging system. (2008) (8)
High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma (2008) (8)
Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma. (2005) (8)
Serum β2-Microglobulin (1986) (8)
Infectious mononucleosis mimicking a B cell immunoblastic lymphoma associated with an abnormality in regulatory T cells. (1985) (8)
Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation (2005) (8)
Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone. (2008) (8)
A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis (2010) (8)
S‐phase fraction by the labeling index as a predictive factor for progression and survival in low grade non‐Hodgkin's lymphoma (1995) (7)
A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients. (2009) (7)
Thymic cyst presenting as an acute mediastinal mass. (1973) (7)
Dendritic cell-based idiotype vaccination for primary systemic amyloidosis (2000) (7)
Primary plasmacytoma at the site of exit wounds after electrical injury (1998) (7)
Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation (2008) (6)
A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02). (2005) (6)
Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT). (2011) (6)
Detection of peripheral blood myeloma cells by three-color flow cytometry. (1995) (6)
Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis (2010) (6)
Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination. (2005) (6)
In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders. (2005) (5)
Bone marrow aspirate immunofluorescent and bone marrow biopsy immunoperoxidase staining of plasma cells in histologically occult plasma cell proliferative marrow disorders. (1994) (5)
Systemic capillary leak syndrome. Long-term follow up (1996) (5)
Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index. (1999) (5)
Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort (2011) (5)
Reply to ‘Rituximab in CD20 positive multiple myeloma’ by P Moreau et al. (2008) (5)
Primary Systemic Amyloidosis (AL): A Randomized Trial of Colchicine vs. Melphalan And Prednisone vs. Melphalan, Prednisone, and Colchicine. (1991) (5)
Analysis of Outcome after Autologous Stem Transplantation in Patients with Newly Diagnosed Myeloma: Comparison of Different Induction Regimens. (2006) (5)
Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM). (2006) (5)
A Prospective Study of CD38/45 Flow Cytometry and Immunofluorescence Microscopy to Detect Blood Plasma Cells in Patients with Plasma Cell Proliferative Disorders (2000) (5)
Prognostic Value of Syndecan-1 in Multiple Myeloma and its Relationship with Other Prognostic Factors. (2004) (5)
Combining Measurements of Plasma Cell Apoptosis and Proliferation in Multiple Myeloma Identifies Patients with Poor Survival. (2005) (4)
Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma (2009) (4)
The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM). (2005) (4)
Treatment paradigms for the newly diagnosed patient with multiple myeloma. (2005) (4)
Serum beta 2-microglobulin. (1986) (4)
Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome (2008) (4)
Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function (2010) (4)
Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials (2008) (4)
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (4)
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. (2009) (4)
Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease. (2008) (4)
Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis. (2005) (4)
Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex). (2008) (4)
Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma. (2003) (4)
A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma. (2009) (4)
AT-101, a Small Molecule Inhibitor of Bcl-2 Family Proteins, Has Significant In Vitro Activity in Multiple Myeloma. (2005) (3)
Circulating plasma cells detected by flow cytometry as a predictor of survival in patients with newly diagnosed multiple myeloma (2005) (3)
Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis (2011) (3)
Proteasome B Subunit Pharmacogenomics : Gene Resequencing and Functional Genomics (2008) (3)
Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma (2012) (3)
Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney (2008) (3)
Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy. (2004) (3)
Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience. (2011) (3)
Incorporation of the plasma cell labeling index into the international staging system of multiple myeloma: Impact on prognostic value (2008) (3)
of multiple myeloma patients Detection and quantitation of malignant cells in the peripheral blood (2011) (3)
Platelet cold agglutinins (1975) (3)
Primary Therapy with Bortezomib—the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02. (2008) (3)
Improving Survival in Multiple Myeloma: Impact of Novel Therapies. (2007) (3)
A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma. (2004) (3)
Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (2011) (3)
A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289) (2010) (2)
Phase II trial of amsacrine in patients with multiple myeloma. (1989) (2)
Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison. (2006) (2)
Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. (2005) (2)
Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma. (2009) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. (2006) (2)
Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B. (2005) (2)
A Phase II Trial of Autologous Stem Cell Transplant (AHSCT) Followed by Mini-Allogeneic Stem Cell Transplant (AlloTx) for the Treatment of Multiple Myeloma: Analysis of ECOG E4A98. (2007) (1)
SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure. (2005) (1)
Communications to the EditorTo the Editor (1987) (1)
A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma (2009) (1)
Staging of Multiple Myeloma (2014) (1)
Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma (2004) (1)
6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival. (2005) (1)
TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia (2008) (1)
Progression risk for MGUS and SMM (2007) (1)
Eligibility f or H ematopoietic S tem-Cell T ransplantation for P rimary S ystemic A myloidosis I s a F avorable Prognostic F actor f or S urvival (2001) (1)
Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00). (2007) (1)
Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis. (2009) (1)
Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies (2011) (1)
Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma. (2006) (1)
14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). (2007) (1)
Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis. (2007) (1)
Thalidomide-Induced Neuropathy: In Response (2002) (1)
In-111DAC Is a Novel Technique To Image Multiple Myeloma. (2006) (1)
Clinical and Biological Correlates of CD45 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma. (2004) (1)
Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma. (2004) (1)
Myeloma International Staging System Retains Its Prognostic Value at Disease Relapse. (2007) (1)
Primary Systemic Amyloidosis (AL): Comparison of Melphalan-Prednisone vs. Colchicine Treatment in 101 Cases (1986) (1)
A Comparative Analysis of Chromosome 13 Gene Expression and Copy Number Changes in Multiple Myeloma Using Array-Based Methods. (2005) (1)
Novel therapy with 2-methoxyestradiol (2ME2) for the treatment of relapsed and plateau phase multiple myeloma (2007) (1)
Diagnostic Evaluation of t[4;14] in Multiple Myeloma. (2006) (1)
Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vitro Activity in Multiple Myeloma. (2005) (1)
The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis (2011) (1)
Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma. (2004) (1)
Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component (2011) (1)
Gamma heavy-chain disease involving upper airway. (1985) (1)
Toward a morphologic classification of multiple myeloma? (1999) (1)
Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma. (2006) (1)
Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. (2011) (1)
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (1)
Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM). (2007) (1)
Myeloma (mm) and the t(ll;14)(ql3;q32); increasing evidence for a biologically distinct subset of patients (2000) (0)
Brief report Efﬁcacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma (2011) (0)
heavy chain locus translocations but have frequent 6q deletions Waldenström macroglobulinemia neoplastic cells lack immunoglobulin (2013) (0)
Combination T herapy W ith T halidomide P lus D examethasone for N ewly D iagnosed M yeloma (2002) (0)
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
clinical implications Tumor suppressor p16 methylation in multiple myeloma: biological and (2013) (0)
One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q. (2005) (0)
Autologous Stem Cell Transplantation Provides Additional Cytoreduction Following Induction Therapy in Multiple Myeloma. (2006) (0)
Use of Bisphosphonates in Patients With Myeloma and Renal Failure–Reply–I (2003) (0)
Survival in Primary SyStemic amyloidoSiS (2010) (0)
Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling. (2004) (0)
Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study (2010) (0)
Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03. (2010) (0)
Multi-Parameter Flow Cytometry(FC) Can Detect Proliferating Myeloma Cells After Treatment: Implications for Targeting the Myeloma Proliferative Component (2010) (0)
Prospective R andomized T rial o f M elphalan a nd P rednisone Versus V incristine, C armustine, M elphalan, Cyclophosphamide, a nd P rednisone i n t he T reatment of P rimary S ystemic A myloidosis (1999) (0)
Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes. (2005) (0)
Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. (2004) (0)
Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents. (2006) (0)
Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells. (2004) (0)
Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia. (2005) (0)
Overt Multiple Myeloma Acquired Fanconi Syndrome Is an Indolent Disorder in the Absence of (2013) (0)
Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation. (2006) (0)
High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma. (2006) (0)
PLASMA CELL LABELING INDEX, BETA 2-MICROGLOBULIN, AND C-REACTIVE PROTEIN :WHATH IS THE BEST COMBINATION FOR MYELOME PROGNOSIS ? AUTHORS' RESPONSE (1993) (0)
Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature. (2005) (0)
B539 Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK (2009) (0)
Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486. (2004) (0)
Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up (2015) (0)
Deletions of 13ql4 in myeloma plasma cells usually represent large deletions of the q arm or monosomy (2000) (0)
Association of High Levels of Free Light Chain and the Presence of Igh Translocations in Multiple Myeloma and Prognostic Implications. (2008) (0)
Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma. (2005) (0)
Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation. (2004) (0)
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light chain amyloidosis (2008) (0)
SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure. (2005) (0)
PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells. (2004) (0)
Cell kinetics and flow cytometry in multiple myeloma (1990) (0)
Plasma Cell Disorders (2011) (0)
Prognostic Value of Bone Marrow Angiogenesis in Newly Diagnosed Multiple Myeloma: A Comparison with Conventional Prognostic Factors. (2005) (0)
Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP) (2007) (0)
Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control. (2008) (0)
significance Genomic abnormalities in monoclonal gammopathy of undetermined (2013) (0)
Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). (2004) (0)
patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience. (2004) (0)
diagnosis and follow-up of patients with POEMS syndrome The utility of plasma vascular endothelial growth factor levels in the (2013) (0)
Genetic Polymorphisms Associated with Clinical Outcome in the Intergroup Trial S9321, Comparing High Dose Therapy with Standard Dose Therapy for Myelomaon, on Behalf of ECOG, SWOG, CALGB, and the Bank on a Cure. (2004) (0)
Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms. (2005) (0)
Multiple myeloma in young patients [3] (multiple letters) (1997) (0)
Prognostic indicators for the diagnosis of multiple myeloma. (2004) (0)
Multiple Myeloma in Young Patients-Reply (1997) (0)
light-chain amyloidosis: long-term results from a phase 2 trial Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for (2012) (0)
Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM). (2009) (0)
Induction of UBC9 and the Sumoylation Pathway in Multiple Myeloma Promotes Plasma Cell Growth and Correlates with Decreased Patient Survival. (2007) (0)
NovelTherapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau PhaseMultiple Myeloma (2007) (0)
myeloma patients treated with high-dose therapy Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in (2013) (0)
early genetic events in patients with primary systemic amyloidosis Translocations involving the immunoglobulin heavy-chain locus are possible (2011) (0)
associated with adverse patient outcome The sumoylation pathway is dysregulated in multiple myeloma and is (2014) (0)
ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models. (2014) (0)
Comparison of MelphalarVPrednisone versus Colchicine (1985) (0)
A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies (2009) (0)
Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes. (2005) (0)
Unraveling Early Mortality In Patients with AL Amyloidosis (2010) (0)
Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM). (2005) (0)
Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients with Previous Diagnosis of Multiple Myeloma (MM). (2009) (0)
Systemic Capillary Leak Syndrome Mimicking Polycythemia Vera. (2006) (0)
Thalidomide-induced neuropathy. Authors' reply (2002) (0)
639P Conditional survival in MM and impact of prognostic factors over time (2022) (0)
IgD Amyloidosis: An Unrecognized Entity (2011) (0)
Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. (2009) (0)
Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure. (2005) (0)
IgH translocations are common in patients with primary systemic amyloidosis (al) (2000) (0)
activity with disease progression in myeloma: evidence favoring loss of marrow angiogenesis inhibitory Bone marrow angiogenic ability and expression of angiogenic cytokines (2013) (0)
A Phase II Study of Alemtuzumab in the Treatment of Plasma Cell Disorders. (2006) (0)
Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab. (2005) (0)
A Local Versus Centralized Processing Comparison of Plasma Cell Isolation, Viability, and RNA Integrity. (2005) (0)
analysis of 411 patients dexamethasone in newly diagnosed multiple myeloma: a comparative Lenalidomide plus dexamethasone versus thalidomide plus (2013) (0)
Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma. (2006) (0)
Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia. (2005) (0)
Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. (2004) (0)
844-3 Preserved radial strain explains normal ejection fraction in cardiac amyloidosis patients with abnormal longitudinal strain (2004) (0)
Absolute Values of Serum Immunoglobulin Free Light Chains Predict for Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. (2005) (0)
Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells. (2005) (0)
survival in 302 patients with newly diagnosed multiple myeloma Circulating plasma cells detected by flow cytometry as a predictor of (2013) (0)
Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM). (2013) (0)
in 168 Cases (2017) (0)
Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma. (2005) (0)
Single Tube 6-Color Flow Cytometry for High Speed, Sensitive Detection of Monotypic Plasma Cells in Plasma Cell Proliferative Disorders. (2006) (0)
Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma (2010) (0)
MULTIPLE MYELOMA IN YOUNG PATIENTS. AUTHORS' REPLY (1997) (0)
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high‐dose cyclophosphamide and α2β interferon versus VBMCP (0)
Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma. (2007) (0)
Greipp on Steroid Responsiveness Lymphoblasts following Hydroxyurea Treatment : Lack of Effect Elevated Glucocorticoid Receptor Binding in Cultured Human (2006) (0)
multiple myeloma patients an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed Blood levels of immune cells predict survival in myeloma patients: results of (2013) (0)
Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma. (2005) (0)
for growth and survival Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philip R. Greipp?

Philip R. Greipp is affiliated with the following schools:

Philip R. Greipp's Academic­Influence.com Rankings

Why Is Philip R. Greipp Influential?

Philip R. Greipp's Published Works

Published Works

What Schools Are Affiliated With Philip R. Greipp?

Philip R. Greipp's AcademicInfluence.com Rankings